Profile data is unavailable for this security.
About the company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
- Revenue in USD (TTM)1.30bn
- Net income in USD326.66m
- Incorporated2007
- Employees834.00
- LocationLantheus Holdings Inc331 Treble Cove RdNORTH BILLERICA 01862United StatesUSA
- Phone+1 (978) 671-8001
- Fax+1 (302) 636-5454
- Websitehttps://www.lantheus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helen of Troy Limited | 2.00bn | 162.04m | 2.37bn | 1.90k | 14.79 | 1.50 | 11.28 | 1.19 | 6.76 | 6.76 | 83.27 | 66.81 | 0.6579 | 2.25 | 4.13 | 1,051,199.00 | 5.33 | 8.62 | 6.46 | 10.82 | 45.95 | 43.16 | 8.10 | 9.72 | 0.9755 | 4.82 | 0.3168 | -- | -6.78 | 6.98 | -35.97 | -0.488 | 66.65 | -- |
| Premier Inc | 1.32bn | 167.33m | 2.54bn | 2.80k | 15.19 | 1.06 | 8.63 | 1.93 | 1.39 | 1.39 | 10.97 | 19.95 | 0.3571 | 4.57 | 3.06 | 470,033.20 | 4.42 | 10.39 | 5.67 | 13.00 | 67.13 | 62.04 | 12.37 | 22.60 | 1.32 | 516.34 | 0.2431 | 19.11 | -6.76 | 2.44 | -34.17 | -15.30 | -2.29 | -- |
| Procept Biorobotics Corp | 136.19m | -105.90m | 2.56bn | 626.00 | -- | 9.08 | -- | 18.78 | -2.24 | -2.24 | 2.88 | 5.53 | 0.3815 | 1.91 | 4.28 | 217,557.50 | -29.66 | -- | -33.47 | -- | 52.17 | -- | -77.75 | -- | 6.77 | -- | 0.1546 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| TransMedics Group Inc | 241.62m | -25.03m | 2.76bn | 584.00 | -- | 20.04 | -- | 11.44 | -0.7685 | -0.7685 | 7.43 | 4.20 | 0.4915 | 2.70 | 5.30 | 413,738.00 | -5.09 | -16.08 | -5.53 | -17.95 | 63.77 | 65.37 | -10.36 | -40.47 | 8.49 | -- | 0.7868 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
| LivaNova PLC | 1.15bn | 17.55m | 2.82bn | 2.90k | 162.40 | 2.21 | 41.61 | 2.45 | 0.3222 | 0.3222 | 21.32 | 23.70 | 0.4883 | 2.76 | 5.79 | 397,774.10 | 0.7472 | -6.01 | 0.8627 | -7.42 | 66.86 | 66.99 | 1.53 | -13.56 | 2.51 | 1.10 | 0.3147 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Enovis Corp | 1.71bn | -54.37m | 3.06bn | 6.55k | -- | 0.8917 | 18.75 | 1.79 | -0.9987 | -0.6117 | 31.33 | 62.61 | 0.3888 | 1.59 | 6.11 | 260,640.80 | -1.23 | -0.3569 | -1.37 | -0.41 | 58.21 | 48.19 | -3.15 | -1.06 | 1.16 | 1.02 | 0.1199 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Axonics Inc | 366.38m | -6.09m | 3.41bn | 797.00 | -- | 5.33 | 535.55 | 9.32 | -0.1285 | -0.1285 | 7.43 | 12.56 | 0.5313 | 1.35 | 7.18 | 459,697.60 | -0.8828 | -12.67 | -0.9601 | -13.76 | 74.94 | 70.04 | -1.66 | -29.68 | 8.98 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
| Envista Holdings Corp | 2.57bn | -100.20m | 3.43bn | 12.80k | -- | 0.8201 | 96.90 | 1.34 | -0.6022 | -0.6022 | 14.65 | 24.34 | 0.3891 | 3.99 | 6.41 | 200,507.80 | -1.52 | 1.94 | -1.79 | 2.34 | 56.52 | 57.65 | -3.90 | 5.29 | 1.90 | 5.12 | 0.2661 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
| Integer Holdings Corp | 1.60bn | 90.65m | 3.91bn | 10.50k | 43.46 | 2.56 | 20.62 | 2.45 | 2.68 | 2.68 | 47.30 | 45.58 | 0.5566 | 5.25 | 5.15 | 152,064.10 | 3.16 | 3.28 | 3.43 | 3.53 | 26.30 | 26.94 | 5.68 | 6.40 | 1.71 | 3.54 | 0.3898 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
| Haemonetics Corporation | 1.27bn | 126.57m | 4.13bn | 3.03k | 32.87 | 4.37 | 18.75 | 3.25 | 2.47 | 2.47 | 24.80 | 18.57 | 0.6229 | 2.11 | 6.47 | 418,649.00 | 6.21 | 4.74 | 7.05 | 5.89 | 53.48 | 49.87 | 9.97 | 7.41 | 1.76 | 26.49 | 0.48 | 0.00 | 17.67 | 5.27 | 166.05 | 9.48 | 8.06 | -- |
| Merit Medical Systems Inc | 1.26bn | 94.41m | 4.18bn | 6.95k | 44.52 | 3.47 | 22.68 | 3.33 | 1.62 | 1.62 | 21.55 | 20.78 | 0.6304 | 2.36 | 7.34 | 180,916.00 | 4.73 | 2.45 | 5.30 | 2.77 | 46.44 | 44.50 | 7.51 | 3.91 | 3.95 | 9.89 | 0.4064 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Lantheus Holdings Inc | 1.30bn | 326.66m | 4.37bn | 834.00 | 13.75 | 5.36 | 11.31 | 3.37 | 4.64 | 4.64 | 18.59 | 11.91 | 0.8723 | 9.46 | 5.21 | 1,554,471.00 | 21.98 | 6.69 | 25.75 | 7.73 | 63.71 | 53.90 | 25.20 | 9.02 | 5.45 | 1,235.43 | 0.4081 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Glaukos Corp | 314.71m | -134.66m | 4.82bn | 907.00 | -- | 10.27 | -- | 15.32 | -2.78 | -2.78 | 6.50 | 9.40 | 0.324 | 1.89 | 8.29 | 346,980.20 | -13.86 | -8.73 | -14.99 | -9.35 | 75.99 | 74.77 | -42.79 | -28.69 | 4.78 | -27.68 | 0.4335 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| Novanta Inc | 881.66m | 72.88m | 5.36bn | 2.90k | 73.87 | 7.95 | 44.88 | 6.08 | 2.02 | 2.02 | 24.47 | 18.80 | 0.7147 | 3.04 | 6.36 | 304,021.40 | 5.91 | 5.46 | 6.74 | 6.34 | 45.36 | 43.24 | 8.27 | 7.71 | 1.91 | 4.83 | 0.3477 | 0.00 | 2.41 | 7.49 | -1.58 | 8.21 | 4.19 | -- |
| DENTSPLY SIRONA Inc | 3.97bn | -132.00m | 6.33bn | 15.00k | -- | 1.92 | 30.01 | 1.60 | -0.6217 | -0.6217 | 18.67 | 15.89 | 0.5282 | 3.00 | 5.98 | 264,333.30 | -1.76 | -1.14 | -2.13 | -1.32 | 52.71 | 53.65 | -3.33 | -2.51 | 0.9467 | 3.63 | 0.3914 | -- | 1.10 | -0.1071 | 86.11 | -- | -4.54 | 9.86 |
Data as of Apr 19 2024. Currency figures normalised to Lantheus Holdings Inc's reporting currency: US Dollar USD
44.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 7.51m | 10.96% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.78m | 9.89% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 3.91m | 5.71% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.40m | 3.50% |
| AllianceBernstein LPas of 31 Dec 2023 | 1.97m | 2.88% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.64m | 2.40% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.57m | 2.29% |
| Westfield Capital Management Co. LPas of 31 Dec 2023 | 1.56m | 2.28% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.52m | 2.22% |
| Reinhart Partners, Inc.as of 31 Mar 2024 | 1.47m | 2.15% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
